{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05878704",
            "orgStudyIdInfo": {
                "id": "GBT021601-014"
            },
            "secondaryIdInfos": [
                {
                    "id": "C5351007",
                    "type": "OTHER",
                    "domain": "Alias Study Number"
                }
            ],
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of GBT021601 in Participants With Renal Impairment",
            "officialTitle": "A Phase I, Open-Label, Single-Dose, Non-Randomized, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Adult Participants With Renal Impairment",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "study-of-in-participants-with-renal-impairment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-19",
            "studyFirstSubmitQcDate": "2023-05-19",
            "studyFirstPostDateStruct": {
                "date": "2023-05-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Renal Impairment study of GBT021601.",
            "detailedDescription": "This is a Phase 1, two-part, non-randomized, open-label, parallel group study to evaluate the PK, safety, and tolerability of GBT021601 following a single dose administration in adult participants with RI."
        },
        "conditionsModule": {
            "conditions": [
                "Renal Impairment"
            ],
            "keywords": [
                "End stage renal disease",
                "Sickle Cell Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment",
                    "type": "EXPERIMENTAL",
                    "description": "GBT021601",
                    "interventionNames": [
                        "Drug: GBT021601"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GBT021601",
                    "description": "Oral",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Concentration of GBT021601 in whole blood and plasma",
                    "description": "To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment (RI)",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Single-dose PK parameters",
                    "description": "To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment",
                    "timeFrame": "Up to 112 Days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs",
                    "description": "To evaluate the safety and tolerability of single dose GBT021601 in participants with renal impairment",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs",
                    "description": "To evaluate the safety and tolerability of GBT021601 in ESRD participants receiving IHD following a single dose",
                    "timeFrame": "Up to 112 Days"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Single-dose PK parameters for GBT021601 in RBC",
                    "description": "To evaluate the single-dose RBC PK of GBT021601 in participants with RI",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Amount of GBT021601 excreted in urine",
                    "description": "To evaluate the urinary excretion of GBT021601 in participants with RI following a single dose",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Descriptive analysis of eGFR versus PK exposure parameters",
                    "description": "The relationship of eGFR, as estimated using serum creatinine and serum cystatin C on GBT021601 PK exposure in participants with RI",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Protein binding of GBT021601 in plasma",
                    "description": "To evaluate the protein binding of GBT021601 in participants with RI",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Single-dose PK parameters for GBT021601 in RBC",
                    "description": "To evaluate the single-dose RBC PK of GBT021601 in participants with ESRD receiving IHD",
                    "timeFrame": "Up to 112 Days"
                },
                {
                    "measure": "Extraction ratio of GBT021601 via dialysis and concentration of GBT021601 in dialysate",
                    "description": "To evaluate the clearance of GBT021601 by IHD in participants with ESRD",
                    "timeFrame": "Up to 112 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females, \u2265 18 years of age at the time of Screening.\n* Have liver (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], and total bilirubin \\[direct and indirect\\]) and renal function tests, Hb, and hematocrit values within normal limits or are not clinically significant at Screening and Day -1 (Cohort 2 only).\n* Has a stable renal function with no clinically significant change in renal status at least 1 month prior to study drug administration.\n\nExclusion Criteria:\n\n* Any clinically significant medical history or abnormal findings upon physical examination, or clinical laboratory tests unrelated to their medical condition related to renal impairment, that might confound the results of the study or pose an additional risk in administering study drug to the participant.\n* Evidence or history of clinically significant allergic (except for untreated, asymptomatic seasonal allergies at the time of study drug administration), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease unrelated to renal impairment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Orange County Research Center",
                    "status": "RECRUITING",
                    "city": "Lake Forest",
                    "state": "California",
                    "zip": "92630",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.64697,
                        "lon": -117.68922
                    }
                },
                {
                    "facility": "Orange County Research Center",
                    "status": "RECRUITING",
                    "city": "Tustin",
                    "state": "California",
                    "zip": "92780",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.74585,
                        "lon": -117.82617
                    }
                },
                {
                    "facility": "Advanced Pharma CR, LLC",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33147",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Nucleus Network",
                    "status": "RECRUITING",
                    "city": "Saint Paul",
                    "state": "Minnesota",
                    "zip": "55114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.94441,
                        "lon": -93.09327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=GBT021601-014"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Renal Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10699",
                    "name": "Kidney Failure, Chronic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M15611",
                    "name": "Sickle Cell Trait",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M207501",
                    "name": "Chrysarobin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}